Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oscar Health, Inc. filings document the public-company disclosures of a healthcare technology and health insurance issuer listed on the New York Stock Exchange under Class A common stock symbol OSCR. Its Form 8-K reports cover operating results, guidance updates, Regulation FD disclosures, material agreements and capital-structure transactions, including credit facilities, convertible notes and debt exchanges.
The company’s proxy materials disclose annual meeting matters, board governance, director elections and executive compensation. Other filings address executive employment arrangements, registered securities, risk language tied to competition, artificial intelligence and machine-learning models, internal controls and the company’s use of technology to support Individual & Family plans, +Oscar services and related healthcare marketplace offerings.
Oscar Health Chief Financial Officer Richard Scott Blackley sold 110,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $25.03 per share. The sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2026, indicating it was pre-arranged. After the sale, he holds 1,106,660 shares directly, and an additional 75,000 shares are held indirectly by the MQB Irrevocable Trust, which includes shares to be issued upon vesting of restricted stock units.
OSCR submitted a Form 144 notice relating to the proposed sale of 110,000 shares of Common Stock consisting of restricted stock units. The filing also records recent 10b5-1 sales by Richard Scott Blackley of 100,000 shares on 05/14/2026 and 19,221 shares on 03/02/2026.
Oscar Health, Inc. Chief Financial Officer Richard Scott Blackley reported open‑market sales of 100,000 shares of Class A Common Stock on May 14, 2026. The filing shows two sale tranches: 8,741 shares at a weighted average price of $23.79 and 91,259 shares at a weighted average price of $23.10.
These transactions were effected under a Rule 10b5‑1 trading plan adopted on February 12, 2026 and executed through multiple trades within price ranges of $22.68–$23.67 and $23.68–$24.09. Blackley also reported indirect ownership of 75,000 shares held by the MQB Irrevocable Trust, alongside his remaining direct holdings.
OSCR reports a Form 144 notice describing a proposed sale of 100,000 Restricted Stock Units and a recent disposition of 19,221 common shares on 03/02/2026.
The filing lists the securities to be sold as Restricted Stock Units dated 05/26/2024 and shows a reported sale by Richard Scott Blackley of 19,221 shares for $257,369.19 on 03/02/2026.
Oscar Health, Inc. delivered sharply stronger results for the quarter ended March 31, 2026. Total revenue rose to $4.65 billion from $3.05 billion, driven by higher premiums as membership grew to about 3.17 million, up roughly 56% year over year.
Net income attributable to Oscar Health, Inc. increased to $679.0 million compared with $275.3 million a year earlier. Diluted earnings per share improved to $2.07 from $0.92. The medical loss ratio improved to 70.5% from 75.4%, reflecting disciplined pricing, favorable claims development, and risk‑adjustment dynamics.
Selling, general, and administrative expenses rose with growth, but the SG&A expense ratio edged down to 15.2%. Cash and cash equivalents increased to $4.81 billion, and total assets reached $9.29 billion. Management highlights regulatory changes, risk‑adjustment uncertainty, and potential new drug‑related tariffs as key external factors that could influence future medical costs and membership.
Oscar Health, Inc. reported strong results for the quarter ended March 31, 2026, and reaffirmed its full-year 2026 guidance. Total revenue reached $4.6 billion, up from $3.0 billion a year earlier, driven by higher membership and rate increases.
The medical loss ratio improved to 70.5% from 75.4%, and the SG&A expense ratio edged down to 15.2% from 15.8%, reflecting disciplined pricing and cost control. Earnings from operations were $704.1 million, with net income attributable to Oscar of $679.0 million, or $2.07 diluted EPS, versus $275.3 million, or $0.92, in 2025.
Adjusted EBITDA was $727.1 million, up from $328.8 million. Membership rose to 3.17 million from 2.04 million, entirely in Individual and Small Group offerings following the end of the Cigna+Oscar arrangement. Cash, cash equivalents and restricted cash increased to $4.83 billion as operating cash flow strengthened.
Oscar Health, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 to elect eight directors, approve an advisory say‑on‑pay resolution, and ratify PricewaterhouseCoopers as auditor for 2026. Stockholders of record on April 10, 2026 may vote online, by phone, or by mail.
The Board will move to eight members as former chair Jeffery Boyd steps down and independent director Siddhartha Sankaran becomes chair. All three Board committees are 100% independent. The company highlights 41% revenue CAGR from 2023–2025, 2025 revenue of $11.7 billion, and market share rising from 17% to 30%, with 3.4 million members as of February 1, 2026.
Executive pay emphasizes performance-based equity. For 2025, the executive bonus pool was funded at 91% of target, below the 105.9% formulaic outcome. CEO Mark Bertolini received no new equity in 2025, but his employment was extended through at least April 1, 2029, with 2026 RSU and PSU awards tied to relative total stockholder return.
Oscar Health, Inc. reaffirmed its full year 2026 guidance that was originally provided with its fourth quarter and full year 2025 results. The company also reminded investors it plans to release first quarter 2026 financial results before the market opens on May 6, 2026, followed by a conference call at 8:00 AM (ET).
Oscar announced that independent director Siddhartha Sankaran will become Chair of the Board effective June 4, 2026, succeeding Jeffery Boyd, who is not standing for reelection at the upcoming annual meeting. The company highlights Sankaran’s extensive insurance industry and board experience, and both Boyd and Sankaran emphasize Oscar’s positioning for future growth and its role in the individual health insurance market.
Sankaran Sid reported acquisition or exercise transactions in this Form 4 filing.
Oscar Health, Inc. director Sid Sankaran received a grant of 1,203 deferred stock units, each representing the right to one share of Oscar Health Class A common stock. The units were issued in lieu of cash retainer payments for board service, using the $14.54 April 9, 2026 closing share price to calculate the grant size.
The deferred stock units are 100% vested on the grant date and will be settled in either cash or Class A shares, at the company’s discretion, within 45 days after the earliest of termination of service, a change in control, death, or disability.